Valoctocogene Roxaparvovec
Clotting Disorders
BioMarin Pharmaceuticalgene_therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Clotting Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Beriplex® P/N CSL Behring | Phase 3 | BB |
Factor Ix National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | BB |
Kcentra CSL Behring | Phase 3 | BB |
Rifaximin University of Roma La Sapienza | Phase 4 | B |
Fresh Frozen Plasma CSL Behring | Phase 3 | B |
View all 10 →
Same molecule, other indications
Valoctocogene Roxaparvovec is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →